SEARCH:   Advanced

Blood, Vol. 113, Issue 25, 6304-6314, June 18, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef IL-7 administration drives T cell–cycle entry and expansion in HIV-1 infection Blood Sereti et al. 113: 6304 Supplemental materials for: Sereti et al ACTG 5214 team Irini Sereti, M.D.1, Michael M. Lederman, M.D.2, Lawrence Fox, M.D., Ph.D.3, Catherine A. Battaglia, M.P.H.4, John Spritzler, Sc.D.5, Evgenia Aga, Sc.M.6, Julie Dudeck, M.P.H.7; Lynette Purdue, Pharm.D.8, Alan Landay, Ph.D.9, Savita Pahwa, M.D.10, Robert Coombs, M.D., Ph.D.11, David Asmuth, M.D.12, Margaret Fischl, M.D.13, Guido Silvestri, M.D.14, Allan Tenorio, M.D.15, Ann Conrad, R.N., A.C.R.N.16, Kathleen A. Medvik, B.S., M.T. (A.S.C.P.)17, Robert Levaro, Renaud Buffet, M.D.18, Julie Engel, Ph.D.19, Mary Dobson, B.S.7, Eric Stets, B.S.7 1The National Institute of Allergy and Infectious Diseases , National Institutes of Health, Bethesda, MD; 2Case Western Reserve University, University of Hospitals of Cleveland, Cleveland, OH, 3Therapeutics Research Program, HIV Research Branch, Division of AIDS, The National Institute of Allergy and Infectious Diseases , National Institutes of Health, Bethesda, MD; 4ACTG Operations Center, Social & Scientific Systems, Inc., Silver Spring, MD; 5Statistical & Data Analysis Center, Harvard School of Public Health, Immunology RAC, Adult Division,Boston, MA ; 6Statistical Data and Analysis Center, Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA; 7Frontier Science and Technology Research Foundation Amherst, NY, 8Pharmaceutical Affairs Branch, Division of AIDS, The National Institute of Allergy and Infectious Diseases, Nation Institutes of Health, Bethesda, MD, 9Rush-Presbyterian Medical College, Rush Medical Center, Chicago, IL, 10University of Miami School of Medicine, Miami, FL, 11Division of Virology, Department of Laboratory Medicine, University of Washington, Seattle, WA, 12Division of Infectious and Immunologic Diseases, Department of Internal Medicine, University of California, Davis Medical Center, Sacramento, CA, 13Department of Medicine, University of Miami School of Medicine, Miami, FL, 14Clinical Virology Hospital, University of Pennsylvania, Philadelphia, PA, 15Section of Infectious Diseases, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, 16MetroHealth Medical Center, Cleveland, OH, 17Case Western Reserve University, Cleveland, OH, 18Tucson, AZ, Cytheris, Incorporation, France, 19Cytheris, Incorporation, Rockville, MD. Files in this Data Supplement: Table S1. List of tetramers used in the study (PDF, 18.1 KB) Table S2. Subject enrollment by stratum, randomization arm and dose (PDF, 11.3 KB) Table S3. Grade 2 and 3 toxicities during the study (PDF, 23.6 KB) Figure S1 (JPG, 60.2 KB) - (A) CD4+ and CD8+ T-cell changes from baseline excluding participants who received 60 µg/kg of rhIL-7. (B) Changes from baseline in central memory CD4+ and CD8+ T cells excluding participants who received 60 µg/kg of rhIL-7. Placebo participants are shown in circles (dashed line) and rhIL-7 participants are shown in triangles (solid line). Figure S2 (JPG, 58.3 KB) - (A) Naïve CD4+ and CD8+ T cells decreased significantly on day 1 and small increases in CD8+ T cells were observed on days 14 and 28. (B) Effector memory CD4+ and CD8+ T cells decreased significantly on day 1 and small increases in CD4+ T cells were observed on days 14 and 28. Placebo participants are shown in circles (dashed line) and rhIL-7 participants are shown in triangles (solid line). (C) CD45RA+ effector CD8+ T cells decreased significantly on day 1 and did not change significantly on days 14 or 28. Placebo participants are shown in circles (dashed line) and rhIL-7 participants are shown in triangles (solid line). Figure S3 (JPG, 54.6 KB) - (A) Percent of CD4+ and CD8+ T cells expressing CD127 during study participation excluding participants who received 60 µg/kg of rhIL-7. (B) Percent of activated (CD38+HLA-DR+) CD4+ and CD8+ T cells during study participation excluding participants who received 60 µg/kg of rhIL-7. Placebo participants are shown in circles (dashed line) and rhIL-7 participants are shown in triangles (solid line). Figure S4 (JPG, 53.3 KB) - (A) Increases in CD4+ and CD8+ T cells expressing Ki67 were observed on days 1 and 4 in rhIL-7 recipients. Results shown do not include participants who received 60 µg/kg of rhIL-7. (B) Cycling (Ki67+) CD4+ and CD8+ T cells at all study visits excluding participants who received 60 µg/kg of rhIL-7. Placebo participants are shown in circles (dashed line) and rhIL-7 participants are shown in triangles (solid line). Figure S5. The proportion of Treg CD4+ T cells did not change from baseline significantly in rhIL-7 recipients compared to changes among placebo recipients on day 28 (P=0.481) (JPG, 19.6 KB) - Placebo participants are shown in circles and rhIL-7 participants are shown in triangles. Figure S6. Absolute numbers of peptide-tetramer-binding CD8+ T cells/ µL did not change significantly from baseline on days 4 and 28 (JPG, 42.3 KB) - This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020